ShangPharma Corporation, through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company. It offers various integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies, and academic and research institutions. The company’s services include discovery chemistry, discovery biology and preclinical development, pharmaceutical development, and biologics services. Its discovery chemistry services consist of medicinal chemistry, synthetic chemistry, library generation, and analytical chemistry; and discovery biology and preclinical development services comprise assay development and high throughput screening, pharmacology, reagent generation, and target validation and biomarker research, as well as DMPK, early formulation, in vitro ADME profiling, metabolite identification, bioanalytical services, and non-GLP toxicology. The company pharmaceutical development services include preformulation and formulation, process research and development, analytical development and validation, and research manufacturing; and biologics services consist of therapeutic antibody generation, antibody optimizing and engineering, and analytical services for large molecules. ShangPharma Corporation provides its services primarily in North America, Europe, China, and Japan. The company was founded in 2002 and is headquartered in Shanghai, the People’s Republic of China.